Read by QxMD icon Read

Luminal breast cancer

Trygve Lofterød, Elin S Mortensen, Hawa Nalwoga, Tom Wilsgaard, Hanne Frydenberg, Terje Risberg, Anne Elise Eggen, Anne McTiernan, Sura Aziz, Erik A Wist, Andreas Stensvold, Jon B Reitan, Lars A Akslen, Inger Thune
BACKGROUND: High triglycerides and low levels of high density lipoprotein (HDL)-cholesterol are observed to promote tumor growth. However, whether breast cancer heterogeneity may explain the contradictory influence of triglycerides and cholesterol observed on breast cancer prognosis remains unclear. METHODS: A population-based survival study among 464 breast cancer cases identified within the Tromsø study was conducted. Pre-diagnostic triglycerides, total-cholesterol and HDL-cholesterol were measured, and detailed clinical and histopathological data were obtained...
June 15, 2018: BMC Cancer
Fararjeh-Salah Abdul Fattah, Shih-Hsin Tu, Li-Ching Chen, Yun-Ru Liu, Yen-Kuang Lin, Hang-Lung Chang, Hui-Wen Chang, Chih-Hsiung Wu, Wendy-Hwang Verslues, Yuan-Soon Ho
The transcription factor GATA3 plays a significant role in mammary gland development and differentiation. We analyzed expression of GATA3 in breast cancer (BC) cell lines and clinical specimens from BC patients in Taiwan. Semi-quantitative reverse transcriptase (RT)-polymerase chain reaction (PCR), quantitative real-time PCR carried out to determine the mRNA level of GATA3 from 241 pairs of matched tumor and adjacent normal tissues from anonymous female donors. GATA3 immunohistochemistry (IHC) staining and H-score were performed (n=25)...
June 11, 2018: Human Pathology
Ji Hyung Hong, Yoon Ho Ko, Keunsoo Kang
Invasive ductal carcinoma is the most common type of breast cancer. Here, we provide a whole transcriptome shotgun sequencing (called RNA-seq) dataset conducted with ten samples of invasive ductal carcinoma tissue and three samples of adjacent normal tissue from a single Korean breast cancer patient (luminal B subtype). Differentially expressed genes (DEGs) were identified with a false discovery rate (FDR)-adjusted p -value of 0.05. Gene ontology analysis identified several key pathways, including lymphocyte activation...
June 2018: Data in Brief
Angela Santonja, Alfonso Sánchez-Muñoz, Ana Lluch, Maria Rosario Chica-Parrado, Joan Albanell, José Ignacio Chacón, Silvia Antolín, José Manuel Jerez, Juan de la Haba, Vanessa de Luque, Cristina Elisabeth Fernández-De Sousa, Luis Vicioso, Yéssica Plata, César Luis Ramírez-Tortosa, Martina Álvarez, Casilda Llácer, Irene Zarcos-Pedrinaci, Eva Carrasco, Rosalía Caballero, Miguel Martín, Emilio Alba
Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study is to explore the clinical relevance of Lehmann TNBC subtypes by identifying any differences in response to neoadjuvant chemotherapy among them. We determined Lehmann subtypes by gene expression profiling in paraffined pre-treatment tumor biopsies from 125 TNBC patients treated with neoadjuvant anthracyclines and/or taxanes +/- carboplatin...
May 29, 2018: Oncotarget
Sebastien Rinaldetti, Eugen Rempel, Thomas Stefan Worst, Markus Eckstein, Annette Steidler, Cleo Aaron Weiss, Christian Bolenz, Arndt Hartmann, Philipp Erben
Background: Transcriptome expression studies identified distinct muscle invasive bladder cancer (MIBC) subtypes closely related with breast cancer subclasses. Here we developed a sensitive quantification method for MIBC subclassification (luminal, basal, p53-like). In addition, the subtype specific expression of drug targets has been investigated. Methods: Absolute quantification (nCounter) of a 64-gene panel was performed on MIBC patients (n=47) treated exclusively with radical cystectomy (RC)...
May 25, 2018: Oncotarget
Esra Arslan, Tevfik F Çermik, Fadime D C Trabulus, Esra C K Talu, Şerife Başaran
OBJECTIVE: In this study, primary tumors' fluorine-18-fluorodeoxyglucose (F-FDG) uptake in luminal A, luminal B, triple-negative, and human epidermal growth factor receptor type-2 subtypes of breast cancer was evaluated. In addition, the relationship between the primary tumor maximum standardized uptake value (SUVmax) value and the presence of distant metastasis and axillary involvement was evaluated. PATIENTS AND METHODS: Whole-body F-FDG PET/computed tomography (CT) imaging of 493 patients (mean age; 54...
July 2018: Nuclear Medicine Communications
Giuseppe Bronte, Sara Bravaccini, Sara Ravaioli, Maurizio Puccetti, Emanuela Scarpi, Daniele Andreis, Maria Maddalena Tumedei, Samanta Sarti, Lorenzo Cecconetto, Elisabetta Pietri, Valeria De Simone, Roberta Maltoni, Massimiliano Bonafè, Dino Amadori, Andrea Rocca
Genomic studies have shown that the androgen receptor (AR) pathway plays an important role in some breast cancer subtypes. However few data are present on the concordance between AR expression in primary tumors and metastases. We investigated AR expression by using immunohistochemistry (IHC) in 164 primary tumors and 83 metastases, to explore its distribution in the different tumor subtypes and its concordance between the two sample types and according to sampling time. AR was more highly expressed in luminal A and B than HER2-positive and triple negative primary tumors...
June 8, 2018: Translational Oncology
Atif Ali Hashmi, Samreen Naz, Shumaila Kanwal Hashmi, Zubaida Fida Hussain, Muhammad Irfan, Syed Muhammad Abu Bakar, Naveen Faridi, Amir Khan, Muhammad Muzzammil Edhi
OBJECTIVE: Cytokeratin 5/6 and Cytokeratin 8/18 are basal and luminal markers of breast cancer and they have pathological and prognostic significance in breast cancer. We performed Cytokeratin 5/6 and CK8/18 immunohistochemistry on 150 cases of triple negative breast cancers and association with various clinicopathological features was evaluated. RESULTS: Positive CK5/6 expression was noted in 8% (12 cases) of TNBC while 2.4% (4 cases) showed focal positive (< 10%) and 89...
June 8, 2018: BMC Research Notes
Séverine Guiu, Caroline Mollevi, Céline Charon-Barra, Florence Boissière, Evelyne Crapez, Elodie Chartron, Pierre-Jean Lamy, Marian Gutowski, Céline Bourgier, Gilles Romieu, Joelle Simony-Lafontaine, William Jacot
BACKGROUND: In luminal androgen receptor (AR) tumours, FOXA1 may direct AR to sites occupied by ER in luminal tumours, thus stimulating proliferation. METHODS: AR and FOXA1 expression were evaluated by immunohistochemistry in 333 non-metastatic triple-negative breast cancers (TNBC). Positivity threshold was set at ≥ 1% staining. Lymphocytic infiltration, PD-L1expression, PIK3CA mutations, PTEN defects and BRCA1 promoter methylation were assessed. RESULTS: AR + /FOXA1 + tumours (42...
June 8, 2018: British Journal of Cancer
Barry Gusterson, Connie J Eaves
Human breast cancers referred to as "basal-like" are of interest because they lack effective therapies and their biology is poorly understood. The term basal-like derives from studies demonstrating tumor gene expression profiles that include some transcripts characteristic of the basal cells of the normal adult human mammary gland and others associated with a subset of normal luminal cells. Elucidating the mechanisms responsible for the profiles of basal-like tumors is an active area of investigation...
June 5, 2018: Stem Cell Reports
Ibrahim M Abdel-Salam, Abeer M Ashmawy, Amany M Hilal, Omayma A Eldahshan, Mohamed Ashour
Breast cancer constitutes the second most prevalent cancer in Egypt, the problem which needs more trends in treatment and treatment development either by regimen modification or introducing new drugs, the main objective of this study is to screen the effects of the aqueous-ethanol herbal extract of Luffa cylindrica leaves on different types of breast cancer cell lines representing different molecular sub-types of the disease. The major active constituents of the extract were tentatively identified by LC/MS which revealed the presence of phenolic compounds derivatives and saponin that may responsible in part for the activity of the extract...
June 6, 2018: Chemistry & Biodiversity
Jeannette T Bensen, Mariaelisa Graff, Kristin L Young, Praveen Sethupathy, Joel Parker, Chad V Pecot, Kevin Currin, Stephen A Haddad, Edward A Ruiz-Narváez, Christopher A Haiman, Chi-Chen Hong, Lara E Sucheston-Campbell, Qianqian Zhu, Song Liu, Song Yao, Elisa V Bandera, Lynn Rosenberg, Kathryn L Lunetta, Christine B Ambrosone, Julie R Palmer, Melissa A Troester, Andrew F Olshan
BACKGROUND: MicroRNAs (miRNAs) regulate gene expression and influence cancer. Primary transcripts of miRNAs (pri-miRNAs) are poorly annotated and little is known about the role of germline variation in miRNA genes and breast cancer (BC). We sought to identify germline miRNA variants associated with BC risk and tumor subtype among African-American (AA) women. METHODS: Under the African American Breast Cancer Epidemiology and Risk (AMBER) Consortium, genotyping and imputed data from four studies on BC in AA women were combined into a final dataset containing 224,188 miRNA gene single nucleotide polymorphisms (SNPs) for 8350 women: 3663 cases and 4687 controls...
June 5, 2018: Breast Cancer Research: BCR
Oswaldo A Lozoya, Janine H Santos, Richard P Woychik
To life scientists, one important feature offered by RNAseq, a next-generation sequencing tool used to estimate changes in gene expression levels, lies in its unprecedented resolution. It can score countable differences in transcript numbers among thousands of genes and between experimental groups, all at once. However, its high cost limits experimental designs to very small sample sizes, usually N = 3, which often results in statistically underpowered analysis and poor reproducibility. All these issues are compounded by the presence of experimental noise, which is harder to distinguish from instrumental error when sample sizes are limiting (e...
2018: Frontiers in Genetics
Federica Baldassari, Carlotta Zerbinati, Marco Galasso, Fabio Corrà, Linda Minotti, Chiara Agnoletto, Maurizio Previati, Carlo M Croce, Stefano Volinia
Background: Breast cancer (BC) represents the most common cancer in women worldwide. Due to its heterogeneous nature, breast cancer management might benefit from differential treatments toward personalized medicine. Additionally, drug resistance is a common phenomenon. We systematically investigated the effect of 14 different drugs administered on BC cell lines in combination with microRNAs (miRNA, miR). Methods: Thirty-eight miRNAs, all associated with BC by clinical and molecular parameters including progression, prognosis and subtypes, were tested for their effects on the viability of 12 different BC cell lines...
2018: Frontiers in Genetics
Dan Zhu, Shuichan Xu, Gordafaried Deyanat-Yazdi, Sophie X Peng, Leo A Barnes, Rama Krishna Narla, Tam Tran, David Mikolon, Yuhong Ning, Tao Shi, Ning Jiang, Heather K Raymon, Jennifer R Riggs, John F Boylan
Historically, phenotypic-based drug discovery has yielded a high percentage of novel drugs while uncovering new tumor biology. CC-671 was discovered using a phenotypic screen for compounds that preferentially induced apoptosis in triple negative breast cancer cell lines while sparing luminal breast cancer cell lines. Detailed in vitro kinase profiling shows CC-671 potently and selectively inhibits two kinases-TTK and CLK2. Cellular mechanism of action studies demonstrate that CC-671 potently inhibits the phosphorylation of KNL1 and SRp75, direct TTK and CLK2 substrates, respectively...
June 4, 2018: Molecular Cancer Therapeutics
Y Li, L Mu, Y X Ruan, Y T Wang, D Zhang, H Zhou, X Wang
Objective: To analyze the relationship between the breast cancer molecular classification and the prognosis of patients underwent breast-conserving therapy and to discuss the safety of the breast conserving surgery from the choice of operation in terms of breast cancer molecular classification. Methods: Clinical data of 618 patients with breast-conserving therapy in Tianjin Medical University Cancer Institute and Hospital from August 2005 to August 2010 were analyzed retrospectively. According to the molecular classification when breast cancer was diagnosed, patients were subdivided into five groups, including Luminal A, Luminal B1, Luminal B2, HER-2-positive and Triple-negative...
May 23, 2018: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
Carlotta Raschioni, Giulia Bottai, Andrea Sagona, Valentina Errico, Alberto Testori, Wolfgang Gatzemeier, Fabio Corsi, Corrado Tinterri, Massimo Roncalli, Libero Santarpia, Luca Di Tommaso
Luminal B breast cancers (BC) have a more aggressive behavior associated with a higher rate of tumor relapse and worse prognosis compared to luminal A tumors. In this study, we evaluated the involvement of specific epithelial-to-mesenchymal transition- (EMT-) and immune-related pathways in the dissemination of luminal B BC cells. The expression of 42 EMT- and immune-related genes was evaluated in matched sentinel lymph nodes (SLNs) analyzed by the one-step nucleic acid amplification assay (OSNA) and primary tumors of 40 luminal B BC patients by gene array and immunohistochemistry...
2018: Disease Markers
Giovanni Corso, Patrick Maisonneuve, Giorgia Irene Santomauro, Alessandra Margherita De Scalzi, Antonio Toesca, Fabio Domenico Bassi, Gabriel Farante, Pietro Caldarella, Mattia Intra, Viviana Galimberti, Paolo Veronesi
OBJECTIVE: The aim of this retrospective study was to assess the risk factors for developing ipsilateral breast tumor reappearance (IBTR) and de novo contralateral breast cancer (BC) after primary BC treatment. METHODS: Retrospectively, 15,168 consecutive patients with primary monolateral BC were enrolled in this monocentric study (from June 1994 to December 2006). Clinicopathological features, follow-up, and survival at 15 years were considered for statistical analysis...
May 30, 2018: Oncology
Margaret M Kozak, Clare E Jacobson, Rie von Eyben, Emily Walck, Erqi L Pollom, Melinda Telli, Kathleen C Horst
PURPOSE: To identify patterns of distant failure (DF) in premenopausal women receiving neoadjuvant chemotherapy (NAC) for breast cancer. PATIENTS AND METHODS: Premenopausal patients treated with NAC between 2005 and 2015 at a single institution were retrospectively reviewed. Timing and location of local, regional, and distant metastases were described. Predictors for DF and overall survival (OS) were analyzed. RESULTS: Of 225 patients, there were 24 (10...
May 7, 2018: Clinical Breast Cancer
Jing-Wei Wang, Xiao-Long Wei, Xiao-Wei Dou, Wen-He Huang, Cai-Wen Du, Guo-Jun Zhang
Notch4, a family member of the Notch signaling pathway, has important roles in cellular developmental pathways, including proliferation, differentiation and apoptosis. The present study aimed to investigate the association between Notch4 expression and clinical outcomes with immunohistochemistry. Notch4 was expressed in 55.6% of triple-negative breast cancer (TNBC), 45.8% of Her-2-overexpressing and 25.5% of luminal breast cancer cases, with significantly higher expression occurring in TNBC (P<0.05). Furthermore, Notch4 expression was inversely associated with estrogen receptor (ER) and/or progesterone receptor positivity, and positively associated with larger tumor size, more lymph node involvement, and more advanced tumor node metastasis stage (P<0...
June 2018: Oncology Letters
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"